Literature DB >> 11930661

Down stream involvement of the bile duct in hepatolithiasis.

Shichun Lu1, Lünan Yan, Linqiang Rao, Tian Xia, Jianlin Gou, Shiyu Zhang, Song Lei.   

Abstract

OBJECTIVE: To evaluate the down stream involvement of the bile duct in hepatolithiasis.
METHODS: Mechanical damage to bile duct epithelia and long standing cholangitis as result of hepatolithiasis play an important role in the carcinogenesis of bile duct epithelia and stricture of the intra- and extra-hepatic bile duct. Macromorphological and microscopic changes in bile duct mucosa of 100 consecutive patients with hepatolithiasis were investigated using intra- or post-operative cholangioscopy. Biopsy specimens of lesions obtained during cholangioscopy were studied with immunohistochemical staining and flow cytometry to determine proliferative activity and DNA content. Five cases of well-proven cholangiocarcinoma were simultaneously studied as controls.
RESULTS: Of the 100 patients, those with chronic cholangitis accounted for 86% (86/100), proliferative lesions 11% (11/100), adenomatous polyps 1% (1/100), and adenocarcinoma 2% (2/100). The obvious mucosal lesion associated with hepatolithiasis was located down-stream of the bile duct, predominantly in the hilar region, e.g. orifices of the right/left hepatic duct and common hepatic duct (73% mucosa lesions in the hilar region). The intensity of cancer embryonic antigen stain and the proliferative cell nuclear antigen index increased with the development of bile duct lesions. Aneuploid DNA presented mainly in the high degree malignant adenocarcinomas (> 80% of cases).
CONCLUSIONS: The obvious mucosal lesions associated with hepatolithiasis were located down-stream of the bile duct, predominantly in the hilar region (73% of mucosal lesions). The proliferative activity of examined bile duct mucosa lesions increased with the development of pathological deterioration, which may contribute to the development of hilar bile duct stricture and hilar cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11930661

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  2 in total

Review 1.  Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis.

Authors:  Fu Yu Li; Nan Sheng Cheng; Hui Mao; Li Sheng Jiang; Jing Qiu Cheng; Quan Sheng Li; Sanjay Munireddy
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

2.  Treatment of chronic proliferative cholangitis with c-myc shRNA.

Authors:  Fu-Yu Li; Nan-Sheng Cheng; Jing-Qiu Cheng; Hui Mao; Li-Sheng Jiang; Ning Li; Sheng He
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.